Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00214942 | Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain | PHASE3 | COMPLETED | - | — | — | Sep 1, 2005 | - | May 9, 2014 | 17 | United States |
| Name | Type | Description |
|---|---|---|
| ORAVESCENT Fentanyl Citrate | DRUG | - |
Inclusion Criteria: Patients are included in the study if all of the following criteria are met: * The patient is willing to provide written informed consent to participate in this study. * The patient is 18 through 80 years of age. * Women must be surgically sterile, 2 years postmenopausal, or, i...